Herceptin Articles
Genentech sales up 15%, but loss incurred
20 July 2000
Chiron files lawsuit against Genentech
12 June 2000
Genentech warns of Herceptin deaths
5 May 2000
TLC suffers as FDA requests more data
4 February 2000
Healthy full-year results for many US pharmaceutical companies
27 January 2000
$180M lawsuit bill hits Genentech earnings
21 January 2000
Cell Genesys gets $4.5m payment for GVAX cancer vaccine
13 December 1999
Decision Resources reviews ovarian cancer market
15 November 1999
Roche reducing stake in Genentech
11 October 1999
TLC initiates Evacet trial with Herceptin
6 August 1999
Herceptin approved in Europe
3 August 1999
sNDA filed for Taxol plus Herceptin
24 June 1999
Herceptin follow-up data show further benefit
20 April 1999
Genentech's 1st qtr product sales leap 42%
15 April 1999
FDAMA Fast-Track Development Proposals
23 November 1998
World's Biggest Biotech Plant For Genentech
28 October 1998
US Majors Post Strong Earnings For 3rd Quarter
15 October 1998
Roche Reports 32% Surge In 9 Months 1998 Sales
12 October 1998
Herceptin Due For October Launch In The USA
1 October 1998
Herceptin Heads Cancer Drugs Backed In USA
10 September 1998
US Advisory Panel Meetings
22 July 1998
First Half Sales At Roche Leap 41%, Boosted By BM
13 July 1998
Roche Licenses Breast Cancer Antibody
9 July 1998
New York Stock Comment
21 May 1998
Herceptin Data Live Up To Expectations
20 May 1998
Genentech Files BLA For Herceptin
5 May 1998
Xenical Recommended For Approval By CPMP
16 April 1998
FDA Approval News In Brief
2 April 1998
Genentech And Dako In Breast Cancer Deal
5 March 1998
Genentech Progress With Breast Cancer Antibody
29 December 1998
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
